查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1976433

凝血因子治療市場：依產品類型、適應症、劑型、最終用戶和通路分類－2026-2032年全球預測

Coagulation Factor Concentrates Market by Product Type, Indication, Formulation, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，凝血因子濃縮物市場價值將達到 95.9 億美元，到 2026 年將成長至 104 億美元，到 2032 年將達到 171.4 億美元，複合年成長率為 8.64%。

主要市場統計數據
基準年 2025 95.9億美元
預計年份：2026年 104億美元
預測年份 2032 171.4億美元
複合年成長率 (%) 8.64%

清楚描繪凝血因子濃縮物不斷變化的格局，將治療創新、臨床可用性、監管預期和供應彈性聯繫起來。

凝血因子濃縮物的市場環境正處於先進生物製藥生產技術、不斷發展的臨床通訊協定和強化的供應鏈監控的交匯點。本文概述了影響包括醫院、專科治療中心和分銷合作夥伴在內的相關人員決策的治療、營運和商業因素。文章強調了可靠的產品供應對於出血性疾病患者至關重要，並指出凝血因子濃縮物在按需治療和預防性治療中都不可或缺。

科學突破、不斷發展的照護模式和不斷加強的供應鏈正在重塑凝血因子濃縮物的治療選擇和商業策略。

凝血因子濃縮物領域正經歷一系列變革，這些變革的驅動力來自科學進步、治療模式的演變以及對供應鏈完整性日益成長的關注。重組技術和製劑研發的進步不斷延長給藥間隔並減少液體負荷，促使臨床醫生重新評估預防性治療方法，並使患者除了關注療效指標外，還能考慮生活品質的改善。同時，基因療法和非凝血因子療法等新型治療方法的引入，正在催生新的臨床終點和患者分層標準，這將影響長期的需求模式和治療流程。

該分析預測了計劃於 2025 年實施的關稅調整對採購、製造業採購和合約模式的連鎖反應，以及這些調整將如何影響准入和成本動態。

美國計劃於2025年實施的政策變化和關稅調整，為製造商和醫療保健採購商帶來了新的成本動態和採購考量。關稅導致的投入成本增加，可能會對整個上游供應鏈造成壓力，尤其是那些依賴跨境採購特殊試劑、一次性技術和輔助包裝組件的生產商。為此，製造商正在評估近岸外包、雙重採購策略以及合約保障措施，以維持獲利能力和供應的連續性。

細分市場對治療方案、臨床工作流程和分銷策略的影響（按產品類型、適應症、製劑形式和醫療機構分類）

了解細分市場的細微差別，有助於闡明治療方法的研發、臨床應用和分銷重點如何因產品、適應症、劑型、最終用戶、分銷管道和給藥途徑的不同而有所差異。產品類型的區分主要圍繞在血漿衍生濃縮物和重組產品展開，重組產品可進一步分為長效型半衰期和標準半衰期兩種類型。這種結構上的二分法會影響生產過程的複雜性、藥物動力學以及在預防醫學中的定位。

區域監管條件、血漿供應韌性和商業模式如何導致美洲、歐洲、中東和非洲以及亞太地區的准入途徑存在差異。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的臨床實踐、監管時間表和供應鏈設計有不同的影響。在美洲，專業血友病治療中心的集中分佈和完善的報銷機制支持了先進重組療法的快速引入。然而，該地區也面臨支付方准入政策的不平衡以及生技藥品低溫運輸物流環境的複雜性。

競爭優勢的形成，源自於製造技術訣竅、重組技術創新、策略夥伴關係以及基於真實世界臨床數據的結果，這些結果決定了准入和臨床部署。

凝血因子濃縮物市場的競爭格局由成熟的血漿衍生產品生產商、重組生物製藥生產商以及專注於延長半衰期設計和替代療法的新興創新者組成。成熟的生產者利用血漿分餾技術、捐贈者網路和大規模生產的深厚專業知識，而重組產品生產商則透過分子工程、延長給藥間隔和簡化給藥方案來提高預防性治療的依從性，從而實現差異化競爭。

為製造商和供應商提供切實可行的策略措施，以增強供應韌性，加快重組產品的引入，並使臨床結果與支付方價值保持一致。

產業領導者可以透過一系列有針對性且切實可行的措施來增強韌性和競爭優勢。首先，應實現籌資策略多元化，投資本地製造和契約製造夥伴關係，以降低跨境關稅波動風險，並縮短關鍵材料的前置作業時間。同時，應增加對持續延伸重組藥物平台的投資，這些平台已證實能夠減少給藥頻率並提高用藥依從性，並建構強調降低整體醫療保健成本的衛生經濟學論點。

為了確保分析的嚴謹性，我們採用了穩健的混合調查方法，結合了對臨床醫生的訪談、監管證據的整合以及交叉檢驗的二手資訊。

本分析所依據的研究採用了一種混合方法，結合了定性訪談、有針對性的二手研究以及監管和臨床文獻的整合，從而構建了該領域的多維度視角。透過與血液科醫生、藥屋主任、供應鏈經理和支付方進行結構化訪談，收集了有關臨床實踐模式、檢驗趨勢和准入限制的關鍵資訊。這些訪談內容被用來建構情境並評估對關稅敏感的供應流。

一項綜合策略重點，旨在協調創新技術、供應鏈連續性和支付方合作，以確保永續獲取醫療服務並改善患者療效。

總之，凝血因子濃縮物處於臨床需求與技術進步的策略交會點。重組技術、緩釋製劑和不斷發展的治療模式為改善患者預後和減輕體液負擔提供了重要機會。另一方面，血漿供應、生產流程複雜性和支付方監管等持續存在的挑戰限制了短期實施風險。法規結構和分銷基礎設施的區域差異進一步增加了商業化策略的複雜性，並需要採取針對特定區域的策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 凝血因子治療市場：依產品類型分類

  • 血漿衍生的
  • 重組
    • 延長的半衰期
    • 標準半衰期

第9章：凝血因子治療市場：依適應症分類

  • A型血友病A
    • 溫和的
    • 緩和
    • 嚴重
  • B型血友病
    • 溫和的
    • 緩和
    • 嚴重
  • 血管性血友病
    • 一型
    • II 型
    • III型

第10章：凝血因子製劑市場（依劑型分類）

  • 液體
  • 凍乾粉

第11章 凝血因子治療市場：依最終使用者分類

  • 醫院
  • 專業醫療中心

第12章 凝血因子治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：凝血因子製劑市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 凝血因子產品市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 凝血因子產品市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國凝血因子市場

第17章：中國凝血因子產品市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bayer AG
  • Bio Products Laboratory Limited
  • BIOGEN INC.
  • Biotest AG.
  • Cerus Corporation
  • CSL Limited
  • Emergent BioSolutions Inc.
  • Grifols, SA
  • Kedrion SpA
  • LFB USA
  • Medscape Network
  • Novo Nordisk A/S
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
Product Code: MRR-DD0700E81E59

The Coagulation Factor Concentrates Market was valued at USD 9.59 billion in 2025 and is projected to grow to USD 10.40 billion in 2026, with a CAGR of 8.64%, reaching USD 17.14 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.59 billion
Estimated Year [2026] USD 10.40 billion
Forecast Year [2032] USD 17.14 billion
CAGR (%) 8.64%

A clear framing of the evolving coagulation factor concentrates landscape linking therapeutic innovation, clinical delivery, regulatory expectations, and supply resilience

The landscape of coagulation factor concentrates stands at the intersection of advanced biologics manufacturing, evolving clinical protocols, and intensified supply chain scrutiny. This introduction frames the therapeutic, operational, and commercial dimensions that shape stakeholder decisions across hospitals, specialty treatment centers, and distribution partners. It highlights the criticality of reliable product availability for patients living with bleeding disorders and positions concentrates as indispensable in both on-demand and prophylactic care pathways.

Transitioning from traditional plasma-derived products toward engineered recombinant options, clinicians and procurement teams now weigh efficacy, safety, dosing frequency, and total cost of care when selecting therapies. Concurrently, regulatory expectations and payer assessments increasingly emphasize real-world outcomes, comparative effectiveness, and pharmacoeconomic evidence. The interplay between innovation in extended half-life biologics and the persistent constraints of plasma supply and manufacturing complexity creates both opportunities and pressures for manufacturers, healthcare providers, and policy stakeholders.

In the sections that follow, this introduction provides a foundation for deep-dive analysis, clarifies the principal therapeutic categories and care settings, and sets the stage for actionable recommendations that align clinical practice with resilient commercial strategies.

How scientific breakthroughs, evolving care paradigms, and supply chain reinforcement are reshaping therapeutic choices and commercial strategies in coagulation concentrates

The coagulation factor concentrates sector is undergoing a set of transformative shifts driven by scientific advances, changing care models, and intensified attention to supply chain integrity. Recombinant engineering and formulation work continue to extend dosing intervals and reduce infusion burdens, prompting clinicians to reassess prophylactic regimens and patients to consider quality-of-life benefits alongside efficacy metrics. At the same time, gene therapies and non-factor modalities introduce new clinical endpoints and patient stratification criteria that will influence long-term demand patterns and treatment algorithms.

On the operational side, manufacturers are investing in biologics capacity, process robustness, and cold-chain logistics to meet heightened quality and traceability expectations. Payers and health systems demand stronger real-world evidence and value articulation, which has prompted closer collaboration between clinical stakeholders and industry to generate outcomes data and optimize care pathways. Additionally, digital health tools and telemedicine are reshaping patient monitoring and adherence support, enabling more proactive management of bleeding episodes and better integration of treatment within patients' daily lives.

Taken together, these shifts require companies and providers to balance near-term access imperatives with longer-term innovation strategies, ensuring that therapeutic advances translate into sustainable clinical and commercial value.

Anticipating the ripple effects of 2025 tariff adjustments across procurement, manufacturing sourcing, and contracting arrangements that influence access and cost dynamics

Policy changes and tariff adjustments in the United States slated for 2025 have introduced new cost dynamics and sourcing considerations for manufacturers and healthcare purchasers. Tariff-driven input cost increases can create pressure points along the upstream supply chain, particularly for producers that depend on cross-border procurement of specialized reagents, single-use technologies, or ancillary packaging components. In response, manufacturers are evaluating nearshoring, dual-sourcing strategies, and contractual protections to preserve margin resilience and continuity of supply.

Health systems and specialty pharmacies are adjusting procurement workflows and inventory policies to manage price volatility and to maintain patient access. As a consequence, contracting models are evolving toward longer-term agreements with indexed pricing mechanisms and enhanced service-level commitments. Pharmacy and therapeutics committees are placing greater emphasis on total cost of care and on the comparability of dosing frequency and resource utilization between extended half-life and standard half-life therapies.

Moreover, tariff implications amplify the importance of regulatory harmonization and of proactive engagement with customs and trade authorities to minimize disruption. Clinical teams are collaborating more closely with supply chain directors to preserve therapeutic availability while navigating cost containment, thereby ensuring that tariff-driven adjustments do not translate into compromised patient outcomes.

Segment-driven implications for therapeutic selection, clinical workflows, and distribution strategies across product types, indications, formulations, and care settings

A nuanced understanding of segmentation clarifies how therapeutic development, clinical adoption, and distribution priorities differ across product, indication, formulation, end user, distribution channel, and administration route. Product-type distinctions center on plasma-derived concentrates and recombinant products, with recombinant offerings further differentiated between extended half-life and standard half-life constructs; this structural dichotomy influences manufacturing complexity, pharmacokinetics, and positioning in prophylactic care.

Indication-level nuances matter because treatment intensity and monitoring differ across Hemophilia A, Hemophilia B, and Von Willebrand Disease. Within Hemophilia A and Hemophilia B, stratification into mild, moderate, and severe categories drives considerations around prophylaxis initiation, dosing frequency, and emergency use. Von Willebrand Disease presents its own clinical subtypes-Type I, Type II, and Type III-that shape therapeutic preferences and factor concentrate selection. Formulation choices, whether liquid presentations or lyophilized powders, affect shelf life, cold-chain requirements, and bedside preparation protocols, which in turn influence hospital pharmacy workflows and specialty center administration.

End-user dynamics are concentrated in hospitals and specialty centers where infusion infrastructure, multidisciplinary teams, and acute care capabilities enable complex case management. Distribution channels vary between hospital pharmacies, online pharmacies, and retail pharmacies; each channel brings different inventory turn rates, reimbursement pathways, and patient access mechanisms. Finally, the predominant route of administration remains intravenous, which dictates infusion training, vascular access planning, and nursing workload. Understanding these intersecting segments enables more tailored clinical protocols, targeted commercial approaches, and optimized supply arrangements.

How regional regulatory landscapes, plasma supply resilience, and commercial models shape access pathways differently across the Americas, EMEA, and Asia-Pacific

Regional dynamics influence clinical practice, regulatory timelines, and supply chain design in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, concentrated pockets of specialized hemophilia treatment centers and established reimbursement pathways support rapid adoption of advanced recombinant therapies, while the region also contends with disparities in payer access policies and a complex logistics environment for cold-chain biologics.

In Europe, Middle East & Africa, regulatory harmonization across jurisdictions and centralized procurement mechanisms can create both opportunities for scale and challenges related to country-level reimbursement heterogeneity. Manufacturers must navigate divergent tender processes and align evidence packages to satisfy multiple HTA frameworks. The Asia-Pacific region presents a heterogenous environment where rapid uptake in some markets coexists with nascent treatment infrastructures in others; manufacturers often pursue phased commercialization strategies that reflect local manufacturing partnerships, plasma collection capacities, and evolving payer readiness.

Across regions, resilience of plasma supply, local manufacturing capabilities, and regulatory engagement strategies will determine lead times and the shape of commercial access. Stakeholders should therefore tailor distribution models, clinical evidence generation, and stakeholder outreach to regional specificities while maintaining global quality and traceability standards.

Competitive positioning driven by manufacturing expertise, recombinant innovation, strategic partnerships, and real-world outcomes that determine access and clinical adoption

Competitive dynamics in the coagulation factor concentrates arena are shaped by incumbent plasma-derived manufacturers, recombinant biologics producers, and emerging innovators focused on extended half-life constructs and alternative modalities. Established producers leverage deep expertise in plasma fractionation, donor networks, and large-scale manufacturing, while recombinant players differentiate through molecular engineering, longer dosing intervals, and simplified administration profiles that support prophylaxis adherence.

Partnerships and strategic alliances continue to define competitive positioning, with collaborations between biopharma firms and specialty pharmacies or hospital networks accelerating patient access programs and evidence generation. At the same time, newcomers emphasize niche positioning-targeting specific severity cohorts or rare subtypes such as particular Von Willebrand disease presentations-to build clinical credibility and payer momentum. Manufacturing scale, regulatory track record, and the ability to demonstrate robust real-world outcomes are increasingly decisive factors when health systems evaluate therapeutic options.

Consequently, commercial leaders must balance investment in novel therapeutic profiles with operational excellence in supply continuity and regulatory compliance to maintain competitive advantage and to support long-term patient-centric care models.

Practical strategic measures for manufacturers and providers to fortify supply resilience, accelerate recombinant adoption, and align clinical outcomes with payer value

Industry leaders can strengthen resilience and competitive positioning through a set of targeted, actionable initiatives. First, diversify sourcing strategies and invest in regional manufacturing or tolling partnerships to reduce exposure to cross-border tariff fluctuations and to shorten lead times for critical inputs. Simultaneously, ramp up investment in extended half-life recombinant platforms that demonstrably reduce infusion frequency and improve adherence, while also building the health economic case that highlights total cost of care improvements.

In parallel, deepen engagement with payers and clinical stakeholders by co-designing outcomes studies and registries that capture real-world effectiveness across severity strata and Von Willebrand disease subtypes. Strengthen distribution flexibility by expanding support for specialty and online pharmacy channels while preserving tight integration with hospital pharmacy protocols for acute administration. Operationally, enhance cold-chain oversight, batch traceability, and emergency stock protocols to mitigate the impact of supply disruptions.

Finally, prioritize patient-centric services-such as infusion education, adherence technologies, and homecare enablement-to improve long-term outcomes and to differentiate commercially. Taken together, these measures align clinical benefits with commercial sustainability and organizational resilience.

A robust mixed-method research approach integrating clinician interviews, regulatory evidence synthesis, and cross-validated secondary sources to ensure analytical rigor

The research underpinning this analysis deployed a mixed-method methodology that combined qualitative interviews, targeted secondary research, and synthesis of regulatory and clinical literature to create a multi-dimensional view of the sector. Primary insights were gathered through structured interviews with hematologists, pharmacy directors, supply chain leaders, and payers to validate clinical practice patterns, procurement dynamics, and access constraints. These conversations informed scenario development and the assessment of tariff-sensitive supply flows.

Secondary sources included peer-reviewed clinical studies, regulatory approvals and guidance documents, product labels, and publicly available company disclosures to triangulate product capabilities, safety profiles, and dosing paradigms. The analysis applied rigorous cross-validation between primary and secondary inputs to ensure consistency and to surface divergences that warranted further investigation. Where appropriate, methodological adjustments accounted for regional regulatory differences and for variations in hospital versus specialty center delivery models.

Data quality checks and expert review cycles were integrated throughout the process to strengthen the robustness of conclusions and to ensure that practical recommendations reflect both clinical realities and operational constraints.

Summative strategic priorities that reconcile innovation, supply continuity, and payer engagement to secure durable access and improved patient outcomes

In conclusion, coagulation factor concentrates occupy a strategic nexus of clinical necessity and technological progress. Recombinant science, extended half-life formulations, and evolving care models present meaningful opportunities to improve patient outcomes and to reduce the burden of infusions, while persistent challenges around plasma supply, manufacturing complexity, and payer scrutiny temper near-term execution risks. Geographic differences in regulatory frameworks and distribution infrastructures further complicate commercialization strategies, requiring regionally tailored approaches.

To succeed, stakeholders must align innovation pipelines with operational investments in supply continuity and evidence generation. By integrating patient-centric services, proactive payer engagement, and resilient procurement strategies, manufacturers and providers can deliver measurable clinical benefits without compromising access. The recommendations in this executive summary provide a roadmap for translating scientific advances into durable clinical and commercial outcomes, preserving the central objective of ensuring timely and effective therapy for patients living with bleeding disorders.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Coagulation Factor Concentrates Market, by Product Type

  • 8.1. Plasma Derived
  • 8.2. Recombinant
    • 8.2.1. Extended Half Life
    • 8.2.2. Standard Half Life

9. Coagulation Factor Concentrates Market, by Indication

  • 9.1. Hemophilia A
    • 9.1.1. Mild
    • 9.1.2. Moderate
    • 9.1.3. Severe
  • 9.2. Hemophilia B
    • 9.2.1. Mild
    • 9.2.2. Moderate
    • 9.2.3. Severe
  • 9.3. Von Willebrand Disease
    • 9.3.1. Type I
    • 9.3.2. Type II
    • 9.3.3. Type III

10. Coagulation Factor Concentrates Market, by Formulation

  • 10.1. Liquid
  • 10.2. Lyophilized Powder

11. Coagulation Factor Concentrates Market, by End User

  • 11.1. Hospitals
  • 11.2. Specialty Centers

12. Coagulation Factor Concentrates Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Coagulation Factor Concentrates Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Coagulation Factor Concentrates Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Coagulation Factor Concentrates Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Coagulation Factor Concentrates Market

17. China Coagulation Factor Concentrates Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Bayer AG
  • 18.6. Bio Products Laboratory Limited
  • 18.7. BIOGEN INC.
  • 18.8. Biotest AG.
  • 18.9. Cerus Corporation
  • 18.10. CSL Limited
  • 18.11. Emergent BioSolutions Inc.
  • 18.12. Grifols, S.A.
  • 18.13. Kedrion S.p.A
  • 18.14. LFB USA
  • 18.15. Medscape Network
  • 18.16. Novo Nordisk A/S
  • 18.17. Octapharma AG
  • 18.18. Pfizer Inc.
  • 18.19. Sanofi S.A.
  • 18.20. Takeda Pharmaceutical Company Limited
  • 18.21. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PLASMA DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PLASMA DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PLASMA DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY EXTENDED HALF LIFE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY EXTENDED HALF LIFE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY EXTENDED HALF LIFE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY STANDARD HALF LIFE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY STANDARD HALF LIFE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY STANDARD HALF LIFE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. GCC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GCC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 175. GCC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. GCC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
  • TABLE 177. GCC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
  • TABLE 178. GCC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 180. GCC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. GCC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. G7 COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. G7 COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. G7 COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 205. G7 COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. G7 COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
  • TABLE 207. G7 COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
  • TABLE 208. G7 COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 210. G7 COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. G7 COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. NATO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. NATO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 215. NATO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 216. NATO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
  • TABLE 217. NATO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
  • TABLE 218. NATO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
  • TABLE 219. NATO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 220. NATO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. NATO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)